{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:58Z","timestamp":1790876698022,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["PCS-1409-24099"],"award-info":[{"award-number":["PCS-1409-24099"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.oret.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T06:15:14Z","timestamp":1715408114000},"page":"943-952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-3828","authenticated-orcid":false,"given":"Andrew J.","family":"Barkmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3671-3622","authenticated-orcid":false,"given":"Jeph","family":"Herrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya Sindhu","family":"Swarna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6841-7706","authenticated-orcid":false,"given":"Yihong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-5026","authenticated-orcid":false,"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9295-3225","authenticated-orcid":false,"given":"Rodolfo J.","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9218-3320","authenticated-orcid":false,"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3664-127X","authenticated-orcid":false,"given":"Mindy M.","family":"Mickelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-3183","authenticated-orcid":false,"given":"Rozalina G.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2024.05.003_bib1","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.05.003_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.oret.2024.05.003_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1755-5922.2011.00308.x","article-title":"Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials","volume":"31","author":"Buehler","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.oret.2024.05.003_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2024.05.003_bib5","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000354116","article-title":"Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats","volume":"50","author":"Maeda","year":"2013","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.oret.2024.05.003_bib6","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.bbadis.2014.04.013","article-title":"Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats","volume":"1842","author":"Gon\u00e7alves","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.oret.2024.05.003_bib7","article-title":"Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2024.05.003_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167853","article-title":"The DPP4 inhibitor linagliptin protects from experimental diabetic retinopathy","volume":"11","author":"Dietrich","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2024.05.003_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2024.05.003_bib10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.lfs.2016.01.042","article-title":"Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats","volume":"147","author":"Takakura","year":"2016","journal-title":"Life Sci"},{"key":"10.1016\/j.oret.2024.05.003_bib11","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3803\/EnM.2017.32.3.316","article-title":"Effects of incretin-based therapies on diabetic microvascular complications","volume":"32","author":"Kang","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.oret.2024.05.003_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-018-1011-7","article-title":"Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA","volume":"18","author":"Khat","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.oret.2024.05.003_bib13","article-title":"Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/Parkin-mediated mitophagy in diabetic retinopathy","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oret.2024.05.003_bib14","article-title":"Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1\/2\/cPLA2\/AA\/ROS pathway independent of hypoglycemic","volume":"13","author":"Hu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.oret.2024.05.003_bib15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oret.2024.05.003_bib16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.13232","article-title":"Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"20","author":"Tang","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.oret.2024.05.003_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The reporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.oret.2024.05.003_bib18","doi-asserted-by":"crossref","first-page":"m4856","DOI":"10.1136\/bmj.m4856","article-title":"STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies","volume":"372","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2024.05.003_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1377\/hlthaff.2014.0038","article-title":"Optum Labs: building a novel node in the learning health care system","volume":"33","author":"Wallace","year":"2014","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.oret.2024.05.003_bib20","unstructured":"OptumLabs. OptumLabs and OptumLabs Data Warehouse (OLDW) Descriptions and Citation. n.p.; 2023. Reproduced with permission from OptumLabs. https:\/\/www.optumlabs.com\/."},{"key":"10.1016\/j.oret.2024.05.003_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100852","article-title":"Derivation of an annualized claims-based major adverse cardiovascular event estimator in type 2 diabetes","volume":"3","author":"McCoy","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.oret.2024.05.003_bib22","author":"Polley"},{"key":"10.1016\/j.oret.2024.05.003_bib23","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A\u00a0tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.oret.2024.05.003_bib24","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1309","article-title":"Super learner","volume":"6","author":"van der Laan","year":"2007","journal-title":"Stat Appl Genet Mol Biol"},{"key":"10.1016\/j.oret.2024.05.003_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.oret.2024.05.003_bib26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.oret.2024.05.003_bib27","series-title":"Design and Analysis of Clinical Trials with Time-to-Event Endpoints. Biostatistics Series","first-page":"455","article-title":"Application of time-to-event methods in the assessment of safety in clinical trials","author":"Moore","year":"2009"},{"key":"10.1016\/j.oret.2024.05.003_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.oret.2024.05.003_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000372","article-title":"Advances in the management of type 2 diabetes in adults","volume":"2","author":"Galindo","year":"2023","journal-title":"BMJ Med"},{"key":"10.1016\/j.oret.2024.05.003_bib30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.oret.2024.05.003_bib31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.oret.2024.05.003_bib32","first-page":"S103","article-title":"10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2024.05.003_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108625","article-title":"Utilization and impact of SLGT2 inhibitors among diabetes patients in a nationally representative survey: findings from NHANES 2013-2020","volume":"37","author":"Shen","year":"2023","journal-title":"J\u00a0Diabetes Complications"},{"issue":"suppl 1","key":"10.1016\/j.oret.2024.05.003_bib34","first-page":"S158","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.oret.2024.05.003_bib35","first-page":"S179","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2024.05.003_bib36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC","volume":"64","author":"Lachin","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.oret.2024.05.003_bib37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.oret.2024.05.003_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc20-1815","article-title":"HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression","volume":"44","author":"Bethel","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.oret.2024.05.003_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224549","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: a real-world Korean study","volume":"14","author":"Chung","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2024.05.003_bib40","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4093\/dmj.2022.0221","article-title":"Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists","volume":"47","author":"Lin","year":"2023","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.oret.2024.05.003_bib41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302400229X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302400229X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T08:19:24Z","timestamp":1727684364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302400229X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S246865302400229X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2024.05.003","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}